|
1
|
Sapisochin G and Bruix J: Liver
transplantation for hepatocellular carcinoma: Outcomes and novel
surgical approaches. Nat Rev Gastroenterol Hepatol. 14:203–217.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Parikh ND, Waljee AK and Singal AG:
Downstaging hepatocellular carcinoma: A systematic review and
pooled analysis. Liver Transpl. 21:1142–1152. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Clavien PA, Lesurtel M, Bossuyt PM, Gores
GJ, Langer B and Perrier A: Recommendations for liver
transplantation for hepatocellular carcinoma: An international
consensus conference report. Lancet Oncol. 13:e11–e22. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tan DJH, Lim WH, Yong JN, Ng CH, Muthiah
MD, Tan EX, Xiao J, Lim SY, Pin Tang AS, Pan XH, et al: UNOS
down-staging criteria for liver transplantation of hepatocellular
carcinoma: Systematic review and meta-analysis of 25 studies. Clin
Gastroenterol Hepatol. 21:1475–1484. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Postow MA, Callahan MK and Wolchok JD:
Immune checkpoint blockade in cancer therapy. J Clin Oncol.
33:1974–1982. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim HY, Kim JD, Bae SH, Park JY, Han KH,
Woo HY, Choi JY, Yoon SK, Jang BK, Hwang JS, et al: A comparative
study of high-dose hepatic arterial infusion chemotherapy and
transarterial chemoembolization using doxorubicin for intractable,
advanced hepatocellular carcinoma. Korean J Hepatol. 16:355–361.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
He MK, Liang RB, Zhao Y, Xu YJ, Chen HW,
Zhou YM, Lai ZC, Xu L, Wei W, Zhang YJ, et al: Lenvatinib,
toripalimab, plus hepatic arterial infusion chemotherapy versus
lenvatinib alone for advanced hepatocellular carcinoma. Ther Adv
Med Oncol. 13:175883592110027202021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang MX, Chen D, Zhao YY, Yang B, Jiang
JP, Zeng FJ, Wei L and Chen ZS: Role of selected criteria and
preventive chemotherapy in tumor recurrence after liver
transplantation. Hepatobiliary Pancreat Dis Int. 19:378–383. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu Z, Gao X, Chen F, Tao X, Cai J, Guo J,
Chen X, Tan J and Yang S: Chinese pediatric organ donation with
scheduled cardiac arrest after brain death: A novel China
classification beyond maastricht. Transplant Proc. 47:2836–2840.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xie QY, Liu HY, Guo ZY, Wu YP, He GL, Cai
L, Pan MX and Fu SJ: Case report: One-year delay in the effect of
conversion surgery therapy for advanced hepatocellular carcinoma
after systemic therapy. Front Mol Biosci. 8:8102512021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhou H and Song T: Conversion therapy and
maintenance therapy for primary hepatocellular carcinoma. Biosci
Trends. 15:155–160. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li QJ, He MK, Chen HW, Fang WQ, Zhou YM,
Xu L, Wei W, Zhang YJ, Guo Y, Guo RP, et al: Hepatic arterial
infusion of oxaliplatin, fluorouracil, and leucovorin versus
transarterial chemoembolization for large hepatocellular carcinoma:
A randomized phase III trial. J Clin Oncol. 40:150–160. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nordness MF, Hamel S, Godfrey CM, Shi C,
Johnson DB, Goff LW, O'Dell H, Perri RE and Alexopoulos SP: Fatal
hepatic necrosis after nivolumab as a bridge to liver transplant
for HCC: Are checkpoint inhibitors safe for the pretransplant
patient. Am J Transplant. 20:879–883. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Katariya NN, Lizaola-Mayo BC, Chascsa DM,
Giorgakis E, Aqel BA, Moss AA, Uson Junior PLS, Borad MJ and Mathur
AK: Immune checkpoint inhibitors as therapy to down-stage
hepatocellular carcinoma prior to liver transplantation. Cancers
(Basel). 14:20562022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Abdel-Wahab N, Safa H, Abudayyeh A,
Johnson DH, Trinh VA, Zobniw CM, Lin H, Wong MK, Abdelrahim M,
Gaber AO, et al: Checkpoint inhibitor therapy for cancer in solid
organ transplantation recipients: An institutional experience and a
systematic review of the literature. J Immunother Cancer.
7:1062019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tabrizian P, Florman SS and Schwartz ME:
PD-1 inhibitor as bridge therapy to liver transplantation. Am J
Transplant. 21:1979–1980. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chaudhuri AA, Chabon JJ, Lovejoy AF,
Newman AM, Stehr H, Azad TD, Khodadoust MS, Esfahani MS, Liu CL, et
al: Early detection of molecular residual disease in localized lung
cancer by circulating tumor DNA profiling. Cancer Discov.
7:1394–1403. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Abbosh C, Birkbak NJ and Swanton C: Early
stage NSCLC-challenges to implementing ctDNA-based screening and
MRD detection. Nat Rev Clin Oncol. 15:577–586. 2018. View Article : Google Scholar : PubMed/NCBI
|
